Off-label use of orphan medicinal products: a Belgian qualitative study

被引:15
作者
Dooms, Marc [1 ]
Cassiman, David [2 ]
Simoens, Steven [3 ]
机构
[1] Univ Hosp Leuven, Ctr Clin Pharmacol, Herestr 49, B-3000 Leuven, Belgium
[2] Univ Hosp Leuven, Div Gastroenterol Hepatol, Herestr 49, B-3000 Leuven, Belgium
[3] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Herestr 49,POB 521, B-3000 Leuven, Belgium
关键词
Off-label use; Unlicensed use; Orphan medicinal products; Rare diseases; Safety; Efficacy; PERSPECTIVE;
D O I
10.1186/s13023-016-0507-y
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Off-label use of (orphan) medicinal products for (rare) diseases is quite common but not underpinned by clinical studies to confirm efficacy and safety. No risk-analyses by regulatory agencies are carried out. The objective of this study was to map off-label use of orphan medicinal products in Belgium in terms of attitude towards off-label prescribing, factors influencing off-label prescribing, disclosure of information towards the patient, reporting of off-label use, risks and consequences. Most of the EMA authorized orphan drugs are fully reimbursed in Belgium under well-defined circumstances. Moreover, a "Special Solidarity Fund" takes care of some specific cases eventually prescribed off-label. Methods: Semi-structured interviews with seven physicians with expertise in the treatment with and six experts in the reimbursement of orphan medicinal products in Belgium. This task was performed by five last-year pharmacy students after having studied profoundly the medical literature around off-label prescribing. They had no previous contact with the participants. Results: Most participants do agree with the off-label use if the medicinal product is quite safe and well-tolerated, if the on-label indication is rather general and when all other options have failed in some specific, evidence-based indications, especially in children. Before starting off-label use, the patient/family needs to be fully and clearly informed. The treatment is not reimbursed but sometimes sponsored by the company or by charity funds. Reporting of the outcome is necessary to avoid losing valuable information. The prescriber is responsible and can be held accountable. Conclusions: While there is support from physicians and reimbursement experts, there is also concern in case of off-label use, mainly for reasons of patient safety especially when medicinal products are prescribed off-label in the absence of medical or scientific justification and driven by cost-containment motives.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 16 条
  • [1] [Anonymous], 2020, QUALITATIVE RES HLTH, DOI DOI 10.1002/9781119410867
  • [2] [Anonymous], 2000, Official Journal of the European Communities, P1
  • [3] Association of Off-label Drug Use and Adverse Drug Events in an Adult Population
    Eguale, Tewodros
    Buckeridge, David L.
    Verma, Aman
    Winslade, Nancy E.
    Benedetti, Andrea
    Hanley, James A.
    Tamblyn, Robyn
    [J]. JAMA INTERNAL MEDICINE, 2016, 176 (01) : 55 - 63
  • [4] Off-Label Use of Drugs in Children
    Frattarelli, Daniel A. C.
    Galinkin, Jeffrey L.
    Green, Thomas P.
    Johnson, Timothy D.
    Neville, Kathleen A.
    Paul, Ian M.
    Van den Anker, John N.
    Knight, Matthew
    Alexander, John J.
    Kilpatrick, Sarah J.
    Cragan, Janet D.
    Rieder, Michael J.
    Robb, Adelaide S.
    Sachs, Hari
    Zajicek, Anne
    Haro, Tamar
    Koteras, Raymond K.
    Del Monte, Mark
    [J]. PEDIATRICS, 2014, 133 (03) : 563 - 567
  • [5] Fund Rare Diseases and Orphan Drugs (managed by the King Baudouin Foundation), 2011, REC PROP MEAS BELG P
  • [6] Off-label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authorities
    Gupta, Sandeep Kumar
    Nayak, Roopa Prasad
    [J]. JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2014, 5 (02) : 88 - 92
  • [7] Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession
    Janzen, R. W. C.
    Ludwig, W. D.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2012, 71 (02): : 108 - +
  • [8] Jellouli Y, 2014, RES OFF LABEL USE OR
  • [9] The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs
    Kesselheim, Aaron S.
    Myers, Jessica A.
    Solomon, Daniel H.
    Winkelmayer, Wolfgang C.
    Levin, Raisa
    Avorn, Jerry
    [J]. PLOS ONE, 2012, 7 (02):
  • [10] Reforming Off-Label Promotion to Enhance Orphan Disease Treatment
    Liang, Bryan A.
    Mackey, Tim
    [J]. SCIENCE, 2010, 327 (5963) : 273 - 274